Torbjörn Lundström, MD
AstraZeneca
10
0
10
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Kei Sakamoto, MD, PhD
Sugioka Memorial Hospital, Medical Co. LTA
Shared therapeutic areas:
Worked with same sponsors:
David Crowley, MD
KGK Science Inc.
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Waqar ahmed awan, Phd
Riphah International University
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
Ahmed Elshafeey, Ph.D. Pharma
Genuine Research Center
Shared therapeutic areas:
Suman Wason, MD
Lexicon Pharmaceuticals, Inc.
Shared therapeutic areas:
Suman Sheraz, PhD*
Riphah International University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
Assessment of the Effect of Food on ABT-143 Bioavailability
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects
All 10 trials loaded